NKTR - Nektar Therapeutics Stock Price, Fair Value and News

1.75USD-0.05 (-2.78%)Delayed

Market Summary

USD1.75-0.05

Delayed

-2.78%

NKTR Stock Price

View Fullscreen

NKTR RSI Chart

NKTR Valuation

Market Cap

321.3M

Price/Earnings (Trailing)

-1.82

Price/Sales (Trailing)

3.56

EV/EBITDA

-1.61

Price/Free Cashflow

-1.7

NKTR Price/Sales (Trailing)

NKTR Profitability

EBT Margin

-195.21%

Return on Equity

-139.57%

Return on Assets

-44.65%

Free Cashflow Yield

-58.87%

NKTR Fundamentals

NKTR Revenue

Revenue (TTM)

90.2M

Rev. Growth (Yr)

0.21%

Rev. Growth (Qtr)

-9.4%

NKTR Earnings

Earnings (TTM)

-176.8M

Earnings Growth (Yr)

72.9%

Earnings Growth (Qtr)

13.01%

Breaking Down NKTR Revenue

Last 7 days

-0.6%

Last 30 days

29.6%

Last 90 days

146.5%

Trailing 12 Months

161.2%

How does NKTR drawdown profile look like?

NKTR Financial Health

Current Ratio

6.1

NKTR Investor Care

Buy Backs (1Y)

2.96%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	90.2M	0	0	0
2023	88.8M	87.7M	88.3M	90.1M
2022	103.1M	96.3M	95.0M	92.1M
2021	126.0M	105.5M	100.4M	101.9M
2020	137.0M	162.5M	163.3M	152.9M
2019	1.2B	119.1M	120.6M	114.6M
2018	529.1M	750.5M	971.9M	1.2B
2017	131.3M	133.1M	249.7M	307.7M
2016	180.9M	191.0M	167.4M	165.4M
2015	289.7M	283.9M	211.0M	230.8M
2014	145.7M	140.3M	212.3M	200.7M
2013	86.2M	96.4M	138.9M	148.9M
2012	78.1M	84.5M	75.8M	81.2M
2011	137.1M	111.9M	101.0M	71.5M
2010	93.7M	115.5M	137.3M	159.0M
2009	0	0	0	71.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nektar Therapeutics

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 20, 2024	robin howard w	sold	-13,622	0.68	-20,033	president & ceo
Feb 20, 2024	wilson mark andrew	sold	-5,172	0.68	-7,606	chief legal officer
Feb 20, 2024	zalevsky jonathan	sold	-6,129	0.68	-9,014	chief r&d officer
Nov 17, 2023	zalevsky jonathan	sold	-4,726	0.49	-9,646	chief r&d officer
Nov 17, 2023	robin howard w	sold	-9,739	0.49	-19,877	president & ceo
Nov 17, 2023	wilson mark andrew	sold	-3,517	0.49	-7,179	chief legal officer
Sep 18, 2023	ajer jeffrey robert	sold	-3,007	0.69	-4,359	-
Sep 18, 2023	curet myriam	sold	-3,007	0.69	-4,359	-
Aug 16, 2023	robin howard w	sold	-15,598	0.78	-19,998	president & ceo
Aug 16, 2023	wilson mark andrew	sold	-5,632	0.78	-7,221	chief legal officer

Which funds bought or sold NKTR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-71.3	-41,012	37,045	-%
May 16, 2024	Tidal Investments LLC	new	-	21,515	21,515	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-25.19	167,387	874,056	0.06%
May 15, 2024	DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	unchanged	-	106,563	269,641	-%
May 15, 2024	MARSHALL WACE, LLP	reduced	-38.34	31,956	1,368,250	-%
May 15, 2024	Lido Advisors, LLC	reduced	-5.14	10,382	28,643	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-12,167	-	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	added	1,720	54,247	56,112	0.01%
May 15, 2024	Alyeska Investment Group, L.P.	reduced	-69.62	-989,475	998,914	0.01%
May 15, 2024	Royal Bank of Canada	reduced	-54.12	-	-	-%

Are Funds Buying or Selling NKTR?

Are funds buying NKTR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NKTR

No. of Funds

Unveiling Nektar Therapeutics's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	tcg crossover gp ii, llc	9.9%	20,046,350	SC 13G
Feb 14, 2024	deep track capital, lp	9.65%	18,400,000	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.0%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	6.31%	12,042,873	SC 13G/A
Aug 17, 2023	ra capital management, l.p.	9.8%	18,700,000	SC 13G
Jul 10, 2023	invesco ltd.	2.9%	5,535,430	SC 13G/A
Jul 10, 2023	vanguard group inc	6.37%	12,056,187	SC 13G/A
Jul 07, 2023	blackrock inc.	4.5%	8,604,322	SC 13G/A
Jul 07, 2023	primecap management co/ca/	4.31%	8,149,876	SC 13G/A

Recent SEC filings of Nektar Therapeutics

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 17, 2024	144	Notice of Insider Sale Intent
May 17, 2024	144	Notice of Insider Sale Intent
May 13, 2024	4	Insider Trading
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 17, 2024	8-K	Current Report

Peers (Alternatives to Nektar Therapeutics)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Nektar Therapeutics News

Latest updates

Nektar Therapeutics Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-9.4%	21,639,000	23,885,000	24,144,000	20,499,000	21,594,000	22,023,000	23,625,000	21,585,000	24,822,000	25,009,000	24,921,000	28,330,000	23,647,000	23,462,000	30,033,000	48,847,000	50,573,000	33,862,000	29,218,000	23,315,000	28,222,000
Costs and Expenses	-0.6%	57,066,000	57,396,000	69,008,000	71,098,000	156,304,000	74,492,000	77,926,000	174,421,000	141,382,000	137,919,000	138,517,000	138,535,000	133,039,000	134,183,000	133,083,000	126,556,000	184,204,000	143,500,000	127,958,000	134,285,000	148,909,000
S&GA Expenses	-100.0%	-	17,320,000	21,147,000	17,869,000	21,081,000	21,939,000	22,534,000	20,521,000	27,339,000	32,142,000	29,468,000	29,555,000	31,679,000	27,136,000	26,982,000	24,347,000	26,217,000	27,142,000	23,983,000	22,581,000	25,006,000
R&D Expenses	-8.5%	27,408,000	29,942,000	24,070,000	29,681,000	30,469,000	34,740,000	33,590,000	42,740,000	107,253,000	99,614,000	103,738,000	101,313,000	95,604,000	102,724,000	100,531,000	96,436,000	108,987,000	110,369,000	99,048,000	106,686,000	118,463,000
EBITDA Margin	37.1%	-1.87	-2.98	-3.19	-3.35	-4.51	-3.82	-4.64	-5.30	-4.62	-5.00	-4.79	-4.36	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	647,000	6,204,000	5,428,000	5,425,000	5,231,000	5,226,000
Income Taxes	-20.7%	-35,000	-29,000	-61,000	-47,000	-63,000	3,144,000	-155,000	100,000	126,000	-4,000	112,000	357,000	92,000	128,000	21,000	144,000	200,000	278,000	99,000	99,000	137,000
Earnings Before Taxes	12.5%	-36,837,000	-42,108,000	-45,898,000	-51,169,000	-137,081,000	-56,544,000	-59,204,000	-158,968,000	-90,267,000	-145,649,000	-129,594,000	-125,162,000	-122,875,000	-117,075,000	-108,565,000	-79,856,000	-138,451,000	-111,886,000	-98,486,000	-110,187,000	-119,495,000
EBT Margin	36.3%	-1.95	-3.07	-3.29	-3.46	-4.64	-3.96	-4.78	-5.44	-4.76	-5.13	-4.93	-4.49	-	-	-	-	-	-	-	-	-
Net Income	13.0%	-36,802,000	-42,307,500	-45,837,000	-51,891,000	-135,792,000	-57,671,000	-59,049,000	-160,727,000	-92,768,000	-145,645,000	-129,706,000	-125,798,000	-123,793,000	-117,203,000	-108,586,000	-80,000,000	-138,651,000	-112,164,000	-98,585,000	-110,286,000	-119,632,000
Net Income Margin	35.9%	-1.96	-3.06	-3.30	-3.47	-4.65	-4.02	-4.82	-5.49	-4.79	-5.15	-4.95	-4.51	-	-	-	-	-	-	-	-	-
Free Cashflow	-1.6%	-48,045,000	-47,284,000	-42,154,000	-51,685,000	-52,348,000	-58,215,000	-83,068,000	-75,773,000	-92,627,000	-157,434,000	-104,072,000	-86,182,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.5%	396	398	442	494	562	711	781	862	1,024	1,117	1,277	1,371	1,457	1,539	1,509	1,595	1,888	1,977	2,088	2,100	2,166
Current Assets	-3.3%	320	331	399	441	491	546	599	666	733	796	986	1,056	1,099	1,138	1,044	1,152	1,429	1,422	1,579	1,597	1,490
Cash Equivalents	37.9%	49.00	35.00	65.00	51.00	77.00	88.00	106	78.00	68.00	25.00	54.00	152	150	199	56.00	58.00	227	96.00	81.00	85.00	107
Inventory	0.9%	16.00	16.00	15.00	21.00	20.00	19.00	19.00	17.00	15.00	16.00	15.00	15.00	17.00	15.00	13.00	13.00	14.00	13.00	14.00	13.00	12.00
Net PPE	-7.3%	17.00	19.00	20.00	23.00	27.00	32.00	37.00	40.00	61.00	61.00	59.00	59.00	59.00	60.00	60.00	61.00	62.00	66.00	65.00	65.00	58.00
Goodwill	-	-	-	-	-	-	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00
Liabilities	0.8%	269	267	283	297	321	344	369	403	416	438	476	466	462	461	338	339	592	572	600	542	533
Current Liabilities	2.2%	52.00	51.00	52.00	51.00	60.00	68.00	84.00	105	105	85.00	140	131	124	116	127	124	377	354	125	113	100
Shareholder's Equity	-3.3%	127	131	159	197	241	367	412	459	608	680	802	905	995	1,077	1,171	1,256	1,296	1,405	1,489	1,557	1,634
Retained Earnings	-1.1%	-3,514	-3,477	-3,435	-3,389	-3,338	-3,201	-3,141	-3,082	-2,923	-2,832	-2,687	-2,557	-2,432	-2,309	-2,191	-2,083	-2,003	-1,864	-1,751	-1,652	-1,542
Additional Paid-In Capital	1.0%	3,644	3,608	3,601	3,593	3,585	3,575	3,562	3,549	3,538	3,517	3,492	3,466	3,430	3,389	3,364	3,339	3,307	3,271	3,241	3,210	3,179
Accumulated Depreciation	-100.0%	-	87.00	88.00	108	111	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	-4.1%	184	191	191	190	189	189	188	186	186	183	183	183	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	109	-	-	-	704	-	-	-	3,100	-	-	-	4,100	-	-	-	6,184	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1.8%	-47,888	-47,047	-42,121	-51,523	-51,915	-57,703	-82,887	-74,993	-88,424	-151,538	-101,136	-82,901	-77,085	-98,634	-52,675	-83,903	-78,075	-125,223	-68,641	-53,922	-80,895
Share Based Compensation	-100.0%	-	7,254	8,149	7,966	10,019	12,738	12,518	11,103	20,961	22,405	24,657	23,714	23,898	21,987	23,667	23,371	25,236	25,008	24,880	24,522	25,385
Cashflow From Investing	10.8%	19,258	17,383	56,412	25,171	40,598	40,014	111,395	84,148	130,278	120,197	-830	72,952	10,458	92,740	48,668	157,038	197,767	135,481	58,253	25,290	-12,138
Cashflow From Financing	349925.0%	42,003	12.00	-	18.00	-	103	-	467	938	2,552	3,663	12,167	17,856	148,995	1,531	-241,957	11,077	4,906	6,249	7,306	4,894

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NKTR Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 21,639	$ 21,594
Operating costs and expenses:
Cost of goods sold	8,534	7,060
Research and development	27,408	30,469
General and administrative	20,149	21,081
Restructuring, impairment and costs of terminated program	975	21,193
Impairment of goodwill	0	76,501
Total operating costs and expenses	57,066	156,304
Loss from operations	(35,427)	(134,710)
Non-operating income (expense):
Non-cash interest expense on liabilities related to the sales of future royalties	(5,531)	(6,405)
Interest income	4,220	4,335
Other income (expense), net	(99)	(301)
Total non-operating income (expense), net	(1,410)	(2,371)
Loss before provision for income taxes	(36,837)	(137,081)
Benefit for income taxes	(35)	(63)
Net loss	$ (36,802)	$ (137,018)
Basic net loss per share (in dollars per share)	$ (0.19)	$ (0.73)
Diluted net loss per share (in dollars per share)	$ (0.19)	$ (0.73)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	194,746	188,875
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	194,746	188,875
Product sales
Revenue:
Total revenue	$ 6,034	$ 4,718
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	15,508	16,861
License, collaboration and other revenue
Revenue:
Total revenue	$ 97	$ 15

NKTR Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 48,642	$ 35,277
Short-term investments	240,596	268,339
Accounts receivable	3,617	1,205
Inventory, net	16,238	16,101
Other current assets	10,743	9,779
Total current assets	319,836	330,701
Property, plant and equipment, net	17,475	18,856
Long-term investments	36,778	25,825
Operating lease right-of-use assets	17,267	18,007
Other assets	4,656	4,644
Total assets	396,012	398,033
Current liabilities:
Accounts payable	8,757	9,848
Accrued expenses	24,281	22,162
Operating lease liabilities, current portion	19,368	19,259
Total current liabilities	52,406	51,269
Operating lease liabilities, less current portion	94,710	98,517
Liabilities related to the sales of future royalties, net	117,857	112,625
Other long-term liabilities	4,334	4,635
Total liabilities	269,307	267,046
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2024 or December 31, 2023, respectively	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 191,909 shares and 191,384 shares issued at March 31, 2024 and December 31, 2023, respectively; 183,624 shares and 191,384 shares outstanding at March 31, 2024 and December 31, 2023, respectively;	19	19
Capital in excess of par value	3,644,140	3,608,137
Treasury stock, at cost; 8,285 shares as of March 31, 2024 and none as of December 31, 2023, respectively	(3,000)	0
Accumulated other comprehensive income (loss)	(403)	80
Accumulated deficit	(3,514,051)	(3,477,249)
Total stockholders’ equity	126,705	130,987
Total liabilities and stockholders’ equity	$ 396,012	$ 398,033

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

CEO	Mr. Howard W. Robin
WEBSITE	nektar.com
INDUSTRY	Biotechnology
EMPLOYEES	216

Nektar Therapeutics Frequently Asked Questions

What is the ticker symbol for Nektar Therapeutics? What does NKTR stand for in stocks?

NKTR is the stock ticker symbol of Nektar Therapeutics. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nektar Therapeutics (NKTR)?

As of Fri May 17 2024, market cap of Nektar Therapeutics is 321.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers. The fair value of Nektar Therapeutics is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nektar Therapeutics is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NKTR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nektar Therapeutics a good stock to buy?

The fair value guage provides a quick view whether NKTR is over valued or under valued. Whether Nektar Therapeutics is cheap or expensive depends on the assumptions which impact Nektar Therapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTR.

What is Nektar Therapeutics's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NKTR's PE ratio (Price to Earnings) is -1.82 and Price to Sales (PS) ratio is 3.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nektar Therapeutics's stock?

In the past 10 years, Nektar Therapeutics has provided -0.168 (multiply by 100 for percentage) rate of return.